About Us ++ Who We Are
Biotheryx is a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders, including bifunctional degraders and molecular glues. Our initial focus is deploying the differentiated potential of degraders towards validated targets in cancer and inflammatory disease. Members of our founding and scientific teams previously developed the first U.S. Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and we have applied our expertise in Cereblon binding to build our proprietary PRODEGY platform.
About Us ++ Mission
We are a purpose-driven team, passionate about leveraging our PRODEGY platform to discover and develop targeted protein degraders to address severe unmet patient needs. In doing so, we seek to build Biotheryx into a leader in next-generation targeted protein degradation.
About Us ++ Leadership
Philippe Drouet joined Biotheryx as President and CEO in October 2021. Prior, he served as Chief Commercial Officer at CRISPR Therapeutics, where he shaped the strategy for the launch of the Company’s first allogeneic CAR-T therapies and helped lead the clinical development strategy for the Company’s Phase I clinical assets. Previously, Philippe served as Senior Vice President, Global Oncology at Merck & Co., where he launched and commercialized Keytruda®, drove substantial global oncology revenue and built and led the Company’s Global Oncology Marketing, Access and Pricing organization. Previously, he served as President of Hospira’s U.S. division before Hospira’s acquisition by Pfizer in 2015. Philippe also held roles of increasing responsibility at Novartis Pharmaceutical Corporation, including Vice President U.S. Hematology, General Manager Oncology in Turkey, Global Brand Leader for Gleevec® and Head of Oncology Marketing in Canada. Philippe received an M.S. and B.S. in Chemical Engineering from McGill University in Canada and an M.B.A. from INSEAD in France.
Dr. Leah Fung joined Biotheryx in 2014 and was pivotal in the design and implementation of the Company’s PRODEGY protein degradation platform. As Chief Scientific Officer, she oversees drug discovery and the strategic expansion of Biotheryx’s pipeline. She created Biotheryx’s Cereblon binder library and directed research that resulted in 25 issued U.S. patents covering an extensive range of small molecules, including Biotheryx’s BTX-1188 molecular glue. Prior, Dr. Fung served as Vice President of Medicinal Chemistry at NovoMedix, where she led drug discovery research efforts to discover antifibrotic and breast cancer development candidates entering into IND-enabling studies. Dr. Fung was also Associate Director of Medicinal Chemistry at Structural Genomix and Assistant Director of Medicinal Chemistry at Structural Bioinformatics. At both companies, she led multi-disciplinary research teams to discover novel cancer therapeutics using fragment-based approaches for lead discovery, as well as crystallography and computational methods for lead optimization. Dr. Fung also held leadership positions at Signal Pharmaceuticals and Celgene. Notably, her research at Celgene led to a selective estrogen receptor modulator co-developed by Novartis and advanced into clinical studies for estrogen receptor-positive breast cancer. Dr. Fung was among leading scientists who pioneered high-throughput parallel synthesis technologies and combinatorial chemistries and has authored or co-authored over 20 peer-reviewed publications. Additionally, she is co-inventor on more than 40 issued U.S. patents and hundreds of international patents. Dr. Fung received her B.S. in chemistry from Azusa Pacific University and a Ph.D. in organic chemistry from the University of California, Irvine.
Jeff Caravella joined Biotheryx as Chief Financial Officer in April 2022. Jeff is responsible for all aspects of the Company’s financial operations, including the development and execution of Biotheryx’s financial and corporate strategy. He previously served as Vice President of Finance at Tango Therapeutics, where he played a key role in the completion of their public offering and designed, built and led the finance and accounting organization. Prior, he held finance roles across commercial, business development and operations functions at other publicly held companies, including Editas Medicine, Charles River Laboratories and Johnson & Johnson. During his 10-year tenure at Johnson and Johnson, Jeff spent two years as the Head of Finance for the J&J Boston Innovation Center, where he led the assessment and strategy for multiple successful business development and licensing deals across the J&J business. Jeff earned his M.B.A. and B.S. from Syracuse University.
Sahm Nasseri joined Biotheryx as Chief Business Officer in January 2022. Sahm is responsible for the Company’s business development, corporate strategy, corporate development and program management functions. He previously served as Chief Executive Officer of PYC Therapeutics, where he was instrumental in building out the Company’s U.S. presence and preclinical, clinical and corporate development teams. Prior, Sahm worked at Merck & Co. for seven years as a leader across business development, investor relations and corporate strategy functions involving extensive commercial drug development experience. During this time, he led global strategy for Merck’s growing oncology organization and served as interim Vice President and Global Product Leader for Merck’s HPV Vaccines. Before Merck, Sahm was a Strategy Consultant with McKinsey & Company in Australia. Sahm holds a B.S. in chemical engineering from the University of New South Wales in Sydney and an M.B.A. from Columbia Business School in New York City.
Dr. Aparajita Hoskote Chourasia joined Biotheryx in 2017 and became Vice President of Biology in October 2021 and Vice President of Preclinical and Translational Biology in April 2023. Aparajita leads the full preclinical biology effort for development of targeted protein degraders at Biotheryx. She has been instrumental in identifying targets and establishing assays to assist in drug discovery efforts and has contributed to the development of the Company’s intellectual property. She has accrued expertise in molecular pathways in cancer, tumor metabolism, tumor models, inflammation and assay development while working at Veridex (a Johnson & Johnson company), Novartis Institutes for Biomedical Research and the Brigham and Women Hospital (teaching affiliate of Harvard Medical School). Dr. Chourasia earned her Ph.D. in cancer biology from the University of Chicago, where her research focused on the tumor suppressive function of BNIP3 mediated mitochondrial autophagy in mammary and pancreatic tumorigenesis and its potential as a critical biomarker for early-stage disease diagnosis. Her work led to successful NIH-funded research awards and peer reviewed research articles and reviews. Dr. Chourasia received an M.S. in biochemistry and molecular biology from the University of Illinois, Chicago, and an M.S. in translational science from Howard Hughes Medical Institute.
Dr. Nuzhat Pathan joined Biotheryx as Vice President of Translational Medicine in April 2023. Dr. Pathan is responsible for translational medicine, including biomarker identification and other elements of the translational and clinical development strategy for Biotheryx’s protein degrader programs. Dr. Pathan brings over 20 years of biotech/pharma experience in oncology drug discovery and development. Previously, she was Senior Director, Translational Oncology at Pfizer where she was responsible for clinical biomarker strategy for early and late-stage oncology studies in diverse tumor types including breast, lung, pancreatic cancer and melanoma. At Pfizer, she served as Translational Oncology Lead for multiple programs including gedatolisib, mavertinib, dacomitinib, encorafenib, binimetinib and for combination studies of kinase inhibitors with immuno-oncology agents such as avelumab and pembrolizumab. Prior, she served as Group Leader at the Novartis Institutes for BioMedical Research where she led a biology team of discovery scientists in novel target identification, validation and drug candidate nomination. Prior, she worked at Biogen Idec as a principal scientist and discovery team lead for first-in-class oncology drug targets, both large and small molecules. She received the Leukemia and Lymphoma Fellowship for her postdoctoral studies with Dr. John C. Reed at the Sanford Burnham Prebys Medical Institute. Dr. Pathan obtained her Ph.D. in Cancer Research with a focus on cell signaling from Purdue University.
Sue Huynh joined Biotheryx as Human Resources (HR) Director in August 2022. She is responsible for the strategy and execution of the Company’s Human Resources function. She spent the first 10 years of her career in HR at large corporations, including Hewlett Packard, Goodrich and Life Technologies. She pivoted to smaller companies in 2016 and held a role at WSRP, a professional services firm. As the first HR professional hired by WSRP, Sue created HR programs that focused on the full employee lifecycle, from talent acquisition and leadership development to total rewards. There, she also created a culture and engagement plan that retained and motivated staff across all levels of the company. Sue earned her B.S. in psychology from the University of Utah and an M.A. in HR and industrial relations from the University of Minnesota-Twin Cities.
About Us ++ Board of Directors
Philippe Drouet joined Biotheryx as President and CEO in October 2021. Prior, he served as Chief Commercial Officer at CRISPR Therapeutics, where he shaped the strategy for the launch of the Company’s first allogeneic CAR-T therapies and helped lead the clinical development strategy for the Company’s Phase I clinical assets. Previously, Philippe served as Senior Vice President, Global Oncology at Merck & Co., where he launched and commercialized Keytruda®, drove substantial global oncology revenue and built and led the Company’s Global Oncology Marketing, Access and Pricing organization. Previously, he served as President of Hospira’s U.S. division before Hospira’s acquisition by Pfizer in 2015. Philippe also held roles of increasing responsibility at Novartis Pharmaceutical Corporation, including Vice President U.S. Hematology, General Manager Oncology in Turkey, Global Brand Leader for Gleevec® and Head of Oncology Marketing in Canada. Philippe received an M.S. and B.S. in Chemical Engineering from McGill University in Canada and an M.B.A. from INSEAD in France.
Dr. Rajeev Dadoo is a Managing Partner of SR One based in the San Francisco Bay Area. He joined SR One in 2004 and is an alum of the Kauffman Fellows Program. He has leveraged his broad operational and strategic experience to invest in a number of successful companies, both in the therapeutics space and in healthcare technology. His prior roles have included working in the Competitive Excellence group at GlaxoSmithKline (GSK) on various global projects and at Genentech in technology and clinical development. He has also held product development and business development roles at Bio-Rad Laboratories and Genome Therapeutics. Dr. Dadoo received his B.A. from Knox College, his M.B.A. from the Wharton School of the University of Pennsylvania and his Ph.D. in chemistry from Stanford University.
Ms. Duvall is Chief Financial Officer of Curis, joining the company in August 2022. Prior to joining Curis, Ms. Duvall served as CFO of Genocea Biosciences. Earlier in her career, she held financial leadership positions with Biogen, Bioverativ, Merck, and PricewaterhouseCoopers. Ms. Duvall holds a B.A. in economics and public policy from Colby College and an M.S. in accounting and MBA from Northeastern University. Ms. Duvall is a certified public accountant.
Dr. John Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industry. He most recently served as President and CEO of Anokion and currently serves on the boards of Evelo Biosciences, Aravive, Trishula Therapeutics, Sonata Therapeutics and Humanigen.
Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the Company’s transition from a discovery-stage biotech to one with multiple programs in clinical trials. Prior to FORMA, he held leadership roles of increasing responsibility at Novartis AG, most recently as Senior Vice President and Global Head of Development for Immunology and Dermatology, where he led the development and registration of Cosentyx® and Ilaris®. During his tenure at Novartis, Dr. Hohneker also played a key role in the development, approval and commercialization of several products, including Gleevec®, Tasigna®, Zometa®, Afinitor® and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. He received a B.A. from Gettysburg College and an M.D. from Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School). He completed his internship and residency in internal medicine and his fellowship in medical oncology at the University of North Carolina at Chapel Hill.
Jack Noelke is a Director at Novomedix. He has more than a decade of experience in the investment industry, holding prior roles of increasing responsibility at Morgan Stanley, T. Rowe Price, and MSD Partners. Mr. Noelke earned his B.A., cum laude, from Williams College.
Dr. David Stirling was a Co-Founder of Celgene, and its former Chief Scientific Officer and Executive Vice President, Pharmaceutical Research & Development. He was responsible for initiating the Thalidomide Clinical and Research Program, which led to Celgene’s first clinical product, Thalomid®. Under Dr. Stirling’s leadership, the blockbuster franchise of Thalomid® derivatives (Revlimid®, Pomalyst® and Otezla®) were developed, and these have played a major role in propelling Celgene into the top-tier of public biotechnology companies worldwide. Prior to joining Celgene, Dr. Stirling held various scientific and management positions within the biotechnology group of Celanese Research Company, from which Celgene was spun off. Dr. Stirling received his Ph.D. in biochemistry from the University of Warwick in England, where he studied the industrial applications of novel oxygenase enzymes. Dr. Stirling is the author of numerous publications and holds over 30 U.S. patents.
About Us ++ Scientific Advisory Board
Dr. Aaron Ciechanover is a Distinguished Research Professor in the Technion–Israel Institute of Technology in Haifa. Following national service as military physician (1973-1976), he continued his studies to obtain a D.Sc., Technion in 1982. There, as a graduate student with Dr. Avram Hershko, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. As a post-doctoral fellow with Dr. Harvey Lodish at the Massachusetts Institute of Technology (MIT), he continued his studies on the ubiquitin system and made additional important discoveries. Over the years, it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development. Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, 2003 Israel Prize and the 2004 Nobel Prize (chemistry, shared with Drs. Hershko and Rose). Among many academies, Dr. Ciechanover is member of the Israeli National Academy of Sciences and Humanities, American Academy of Arts and Sciences (Foreign Fellow), American Philosophical Society, U.S. National Academy of Sciences and the Institute of Medicine of the U.S. National Academies (Foreign Associate), and the Russian Academy of Sciences (Foreign Member). He received his M.Sc. and M.D. from Hebrew University in Jerusalem.
Adrian is a board-certified physician scientist with more than 20 years of research and clinical development experience spanning oncology, infectious disease and neuroscience. He received his medical degree and Ph.D. from the University of Leeds, following scientific training in the laboratories at Genentech. Thereafter he completed his residency and fellowship through joint academic and clinical training at the John Radcliffe Hospital and University of Oxford, before joining the faculty of the Nuffield Department of Clinical Laboratory Sciences. He has devoted his career to building and leading high performing teams to accelerate clinical development for small and large molecule therapeutics in industry. Adrian has contributed to the development of approved products including Avastin®, Zemdri®, Tarceva®, Zelboraf®, and Cotellic®, and investigational medicines including MetMAb, Apo2L, anti-DR5, anti-LRRK2, anti-LILRB4, anti-CD96, anti-CD200R1, and anti-PPARG and has authored over 60 peer-reviewed papers.
Dr. Brenda Schulman is Director of the Department of Molecular Machines and Signaling at Max Planck Institute of Biochemistry, Honorary Professor at Technical University of Munich and adjunct faculty at St. Jude Children’s Research Hospital. Dr. Schulman’s research group studies biochemical mechanisms underlying regulation by ubiquitin and autophagy pathways. Her lab has developed methods and tools to probe fleeting intermediates in ubiquitin and ubiquitin-like protein transfer cascades, and implemented them to determine the structural mechanisms of major families of E3 ligases, with a particular focus on dynamic multiprotein complexes including cullin-RING E3 ligases. Dr. Schulman is an elected member of American Academy of Arts and Sciences, the National Academy of Sciences, European Molecular Biology Organization (EMBO), and the German National Academy Leopoldina and has been recognized by awards including most recently the Gottfried Wilhelm Leibniz Prize and Ernst Jung Prize for Medicine. Dr. Schulman received her Ph.D. from Massachusetts Institute of Technology (MIT) studying protein folding with Peter Kim before developing an interest in the regulation of protein degradation during her postdoctoral studies first at Mass General Hospital (MGH) Cancer Center with Dr. Ed Harlow, and then at Memorial Sloan-Kettering Cancer Center with Nikola Pavletich.
Dr. Kevan Shokat is an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco and Professor in the Department of Chemistry at the University of California, Berkeley. Dr. Shokat’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011) and the American Academy of Arts and Sciences (2011). He has commercialized discoveries from his laboratory through co-founding several biotechnology companies, including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines and Kumquat Biosciences. He received his B.A. in chemistry from Reed College and Ph.D. in organic chemistry at University of California, Berkeley with Professor Peter Schultz, and he carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow.
About Us ++ Investors
